How parents can protect babies from RSV

Respiratory syncytial virus is a common illness that causes cold-like symptoms. But for premature babies and those with lung issues, RSV can be fatal.

Most children get RSV. The typical season for this virus is between November to April. But for babies born prematurely, with low birth weight, or with lung or heart problems, the risk is more severe. According to the March of Dimes, preterm babies who get RSV are three times more likely to die from the virus than full-term babies.  

As a practicing obstetrician caring for women of color, Dr. Hasra Snaggs, director, medical monitor, vaccine research development at Pfizer, and an obstetrician specialist has delivered mothers prematurely and recognized the impact of babies being born early.  

“Unfortunately, Black women are 50 percent more likely to give birth to a premature baby than White or Hispanic women,” she says in an email interview. “RSV is of particular concern for Black mothers and infants.” 

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Poolbeg Pharma

More articles like this

Poolbeg Pharma

The growing role of AI in drug discovery

Bringing a new drug to market is an enormously complex and expensive process, often taking over a decade and costing upwards of $2 billion. The pharmaceutical industry faces increasing pressure to improve R&D productivity and efficiency. Artificial intelligence

Poolbeg Pharma

Poolbeg Pharma gets go-ahead for Japanese patent

Dublin-based infectious disease specialist Poolbeg Pharma has received a green light from Japan’s patent office, relating to a patent application for the company’s “potential blockbuster treatment” for severe influenza. The Japanese Patent Office has issued a notice of

Poolbeg Pharma

AI Unleashed: Experts from Poolbeg Pharma & CytoReason

Roundtable discussion featuring Artificial Intelligence hot topics, such as: The future of AI How AI could have contributed to the COVID-19 pandemic Highlights from the exciting collaboration between Poolbeg Pharma and CytoReason. Speakers: Jeremy Skillington – CEO of

Poolbeg Pharma

Poolbeg Pharma plc granted allowance from the Japanese Patent Office

Poolbeg Pharma Plc (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that it has received a notice of allowance from the Japanese Patent Office in relation to its Immunomodulator I patent application. The

Poolbeg Pharma

Poolbeg Pharma patent opposition to be withdrawn

Poolbeg Pharma (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that the opposition to one of its European patents (Immunomodulator I) that was previously filed by a third party is to be

Poolbeg Pharma

AI to revolutionise drug development by 2026

Initial data from the CPHI Annual Report 2023, which provides insight from 250 global pharmaceutical companies, reveals that AI (artificial intelligence) is expected to transform every area of the industry, from drug discovery through to drug development, within the

Poolbeg Pharma

Poolbeg Pharma make significant progress in advancing pipeline

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced its unaudited interim results for the six months to 30 June 2023. Interim Results Highlights and Business Update ·    Strong cash balance

Poolbeg Pharma

Poolbeg Pharma’s Oral Vaccine Platform

By delivering vaccines to the gut, oral vaccines can trigger ‘mucosal immunity’ which prevents pathogens infecting the body by producing a protective response in the areas of the body where there is a high level of infectious threat,

Poolbeg Pharma

AI Unleashed: Featuring Experts from Poolbeg Pharma & CytoReason

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Poolbeg Pharma

The potential benefits of AI in the development of medicines

Warnings about the potential threats of artificial intelligence (AI) technology have been coming from various industries. However, one of Britain’s largest drug firms, GlaxoSmithKline (GSK), believes that the use of cutting-edge AI could have a positive impact on

Poolbeg Pharma

AI will be a game-changer for medicine

Warnings about the potential threats of artificial intelligence (AI) technology have been coming thick and fast from a wide range of industries. But the use of cutting-edge AI could benefit us all by dramatically speeding up the development

Poolbeg Pharma

The role of generative AI in drug discovery

The field of drug discovery is challenging and time-consuming, but generative artificial intelligence (AI) has the potential to revolutionize this process. Generative AI, a subfield of AI, focuses on creating new data instances that resemble existing data. In

No more posts to show